#EyePoint
Pomerantz Law Firm Launches Investigation into EyePoint, Inc. for Shareholder Claims#United_States#New_York#Securities_Fraud#Pomerantz#EyePoint
Pomerantz Law Firm Launches Investigation into EyePoint, Inc. for Shareholder Claims
Pomerantz LLP is probing potential securities fraud claims involving EyePoint, Inc. after significant stock declines due to clinical trial failures.
third-news.com
November 12, 2026 at 4:38 PM
$EYPT — EyePoint Pharmaceuticals' DURAVYU™ trial failure and subsequent workforce reduction dominated recent analyses.

Company beat revenue estimates in Q3 2026. DURAVYU™ trial for wet AMD missed primary endpoint.

https://market-scanner.net/tickers/EYPT.US

#ai #trading
EYPT.US — AI analysis summary
Descriptive, non-directional summary of recent AI analyses.
market-scanner.net
November 16, 2026 at 1:31 PM
$EYPT — Das Scheitern der DURAVYU™-Studie von EyePoint Pharmaceuticals und der anschließende Personalabbau dominierten die jüngsten Analysen.

Genannte Chancen: Das Unternehmen übertraf die Umsatzschätzungen im 3. Quartal 2026.

https://market-scanner.net/de/tickers/EYPT.US

#ai #trading
EYPT.US — Zusammenfassung der KI-Analysen
Beschreibende, richtungsneutrale Zusammenfassung aktueller KI-Analysen.
market-scanner.net
November 16, 2026 at 1:31 PM
November 9, 2026 at 7:05 PM
Technically whining about the reduction in magnification needed to make high-eyepoint finders is ableism
November 6, 2026 at 2:45 PM
Three Massachusetts employers have filed layoff notices impacting 177 workers.

EyePoint US: 105 jobs in Watertown and Northbridge

Powered by FTGU: 62 jobs in Fitchburg

Family Endeavors: 10 jobs statewide

Layoffs are scheduled for December and January.
November 6, 2026 at 11:43 AM
Ophthopedia Update: LUGANO trial fails to meet noninferiority endpoint in wet AMD: NEW ORLEANS — In this video, David A. Eichenbaum, MD, FASRS, said a phase 3 trial that assessed Duravyu for wet age-related macular degeneration “did not meet the primary endpoint of… #ophthalmology #eye #eyenews
LUGANO trial fails to meet noninferiority endpoint in wet AMD
NEW ORLEANS — In this video, David A. Eichenbaum, MD, FASRS, said a phase 3 trial that assessed Duravyu for wet age-related macular degeneration “did not meet the primary endpoint of noninferiority in visual acuity.” In the LUGANO trial, presented at the American Academy of Ophthalmology meeting, patients with wet AMD received either Duravyu (vorolanib intravitreal insert, EyePoint Pharmaceuticals) every 6 months or Eylea (aflibercept 2 mg, Regeneron) every 8 weeks. Nine patients who received Duravyu, formerly known as EYP-1901, experienced vision loss unrelated to macular drying, but when
dlvr.it
November 9, 2026 at 12:04 PM
$EYPT #Biotech #Clinical — EyePoint laid out the scientific calendar for LUCIA and COMO/CAPRI. The calendar sets expectations; the data decide.
https://www.merlintrader.com/eyepoint-stock-hub/
November 6, 2026 at 9:47 PM
$EYPT #Conference #Biotech — EyePoint announces participation at upcoming investor conferences and scientific meetings
https://justcharts.merlintrader.com/?utm_source=bluesky&utm_medium=social&utm_campaign=jc20261107&utm_content=EYPT#EYPT
Visit Justcharts for bull/bear scenarios.
November 7, 2026 at 7:19 AM
Pomerantz Law Firm Probes EyePoint, Inc. for Investor Claims Amidst SEC Concerns#USA#New_York#Pomerantz_LLP#DURAVYU#EyePoint
Pomerantz Law Firm Probes EyePoint, Inc. for Investor Claims Amidst SEC Concerns
Pomerantz Law Firm is investigating potential claims against EyePoint, Inc. amid allegations of securities fraud. Investors may be impacted following recent announcements.
third-news.com
November 6, 2026 at 1:05 AM
Investigation Launched by Pomerantz Law Firm for EyePoint, Inc. Investors Regarding Possible Securities Fraud#USA#New_York#Securities_Fraud#Pomerantz#EyePoint
Investigation Launched by Pomerantz Law Firm for EyePoint, Inc. Investors Regarding Possible Securities Fraud
Pomerantz Law Firm is investigating securities fraud claims for investors of EyePoint, Inc. after disappointing clinical trial results significantly impacted stock prices.
third-news.com
November 6, 2026 at 1:04 AM
EyePoint ($EYPT) – 13G holder trims

• Holder: Federated Hermes
• Stake: 8.04% → 1.59% (about $547K)
• Shares: 6,934,414 → 1,367,142
• Filed: Nov 4 · Schedule 13G/A

📊 Track ownership filings at www.elixstocks.com

Educational purposes only. Not investment advice.

#Investing #Stocks
Federated Hermes, Inc.: 1.59% of EyePoint ($EYPT)
Schedule 13G/A filed Nov 4. Who filed, the stake, and how it changed.
elixstocks.com
November 4, 2026 at 1:08 PM
EyePoint ($EYPT) – 13G holder update

• Holder: Vanguard Capital Management
• Stake: 4.99%, unchanged (about $2M)
• Filed: Oct 30 · Schedule 13G/A

📊 Track ownership filings at www.elixstocks.com

Educational purposes only. Not investment advice.

#Investing #Stocks #13G #ElixStocks
Vanguard Capital Management LLC: 4.99% of EyePoint ($EYPT)
Schedule 13G/A filed Oct 30. Who filed, the stake, and how it changed.
elixstocks.com
October 31, 2026 at 11:05 PM
#$EYPT weekly close $0.35 (-13.9% w/w), below SMA50 $3.21 / below SMA200 $10.98, RSI 15.6. Support $0.34, resistance $3.57. Broad market sell-off Friday.

New hub updated: www.merlintrader.com/eyepoint-sto...
October 31, 2026 at 6:55 AM
#$EYPT weekly close $0.35 (-13.9% w/w), below SMA50 $3.21 / below SMA200 $10.98, RSI 15.6. Support $0.34, resistance $3.57. Broad market sell-off Friday.

New hub updated: www.merlintrader.com/eyepoint-sto...
October 31, 2026 at 6:55 AM
Investors of EyePoint, Inc. Face Legal Scrutiny Amid Disappointing Clinical Trial Results#USA#New_York#Securities_Fraud#Pomerantz#EyePoint
Investors of EyePoint, Inc. Face Legal Scrutiny Amid Disappointing Clinical Trial Results
Pomerantz LLP is investigating potential securities fraud claims against EyePoint, Inc. after significant stock price drops following clinical trial setbacks.
third-news.com
October 29, 2026 at 3:08 PM
Fractyl Health will focus on maintaining weight loss after GLP-1 drugs. EyePoint will prioritize treatment for diabetes-related vision loss. trib.al/WXW7RtJ
Two Mass. biotech companies plan to cut about half their workers
Fractyl Health will focus on maintaining weight loss after GLP-1 drugs. EyePoint will prioritize treatment for diabetes-related vision loss.
trib.al
October 26, 2026 at 6:28 PM
EyePoint just downgraded at Jones
Reported Friday, Oct 23 - 4:03pm EDT (TheFly subscription required to read more.)
thefly.com
October 23, 2026 at 8:10 PM